N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT.

PURPOSE To prospectively compare the diagnostic capability of short inversion time inversion-recovery (STIR) turbo spin-echo (SE) imaging, diffusion-weighted (DW) magnetic resonance (MR) imaging, and fluorodeoxyglucose (FDG) combined positron emission tomography (PET) and computed tomography (CT) in N stage assessment in patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS This prospective study was approved by the institutional review board, and written informed consent was obtained from all patients. A total of 250 consecutive patients with NSCLC (136 men; mean age, 73 years; 114 women; mean age, 72 years) prospectively underwent pretherapeutic STIR turbo SE imaging, DW MR imaging, and FDG PET/CT, as well as surgical and pathologic examinations (N0 disease, n = 157; N1 disease, n = 72; N2 disease, n = 16; N3 disease, n = 5). Lymph node-to-saline ratio (LSR), lymph node-to-muscle ratio (LMR), apparent diffusion coefficient (ADC), maximal standardized uptake value (SUV(max)), and visual scoring were assessed for 135 metastatic lymph nodes and 135 randomly selected nonmetastatic lymph nodes. Receiver operating characteristic curve analysis was used to determine feasible threshold values. Diagnostic capabilities for N stage assessment were compared with the McNemar test on a per-patient basis. RESULTS When feasible, threshold values were used for quantitative assessment; sensitivity and accuracy of LSR and LMR (sensitivity, 82.8%; accuracy, 86.8%) proved to be significantly higher than those of ADC (sensitivity: 74.2%, P = .01; accuracy: 84.4%, P = .04) and SUV(max) (sensitivity: 74.2%, P = .01). For qualitative assessment, sensitivity of STIR turbo SE imaging (77.4%) was significantly higher than that of DW MR imaging (71.0%, P = .03) and FDG PET/CT (69.9%, P = .02). CONCLUSION Quantitative and qualitative assessments of N stage disease in patients with NSCLC obtained with STIR turbo SE MR imaging are more sensitive and/or more accurate than those obtained with DW MR imaging and FDG PET/CT. SUPPLEMENTAL MATERIAL http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.11110281/-/DC1.

[1]  M. Tsuboi,et al.  A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). , 2010, Japanese journal of clinical oncology.

[2]  H. Shirato,et al.  Metastases in Mediastinal and Hilar Lymph Nodes in Patients With Non-Small Cell Lung Cancer: Quantitative Assessment With Diffusion-Weighted Magnetic Resonance Imaging and Apparent Diffusion Coefficient , 2010, Journal of computer assisted tomography.

[3]  Y. Fujibayashi,et al.  The Effectiveness of 18F-FDG PET/CT Combined with STIR MRI for Diagnosing Nodal Involvement in the Thorax , 2008, Journal of Nuclear Medicine.

[4]  P. Boiselle,et al.  Mediastinal Lymph Nodes in Patients With Non-small Cell Lung Cancer: Preliminary Experience With Diffusion-weighted MR Imaging , 2008, Journal of thoracic imaging.

[5]  S. Shiraishi,et al.  Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. , 2008, The Journal of thoracic and cardiovascular surgery.

[6]  Y. Ohno,et al.  STIR turbo SE MR imaging vs. coregistered FDG‐PET/CT: Quantitative and qualitative assessment of N‐stage in non‐small‐cell lung cancer patients , 2007, Journal of magnetic resonance imaging : JMRI.

[7]  Michael K Gould,et al.  Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). , 2007, Chest.

[8]  Michael Wallace,et al.  Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.

[9]  D. Baldwin,et al.  Lung cancer outcomes at a UK cancer unit between 1998-2001. , 2007, Lung cancer.

[10]  D. Collins,et al.  Diffusion-weighted MRI in the body: applications and challenges in oncology. , 2007, AJR. American journal of roentgenology.

[11]  Michael T. Halpern,et al.  EVALUATION OF HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS OF ANEMIA AMONG CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS , 2005 .

[12]  Byung-Tae Kim,et al.  Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. , 2005, Radiology.

[13]  T. Araki,et al.  Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma , 2004, Cancer.

[14]  Y. Ohno,et al.  Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging. , 2004, Radiology.

[15]  Thomas Beyer,et al.  Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. , 2003, Radiology.

[16]  Hiroto Hatabu,et al.  Differentiation of metastatic versus non-metastatic mediastinal lymph nodes in patients with non-small cell lung cancer using respiratory-triggered short inversion time inversion recovery (STIR) turbo spin-echo MR imaging. , 2002, European journal of radiology.

[17]  G. Watanabe,et al.  Peripheral small-sized (2 cm or less) non-small cell lung cancer with mediastinal lymph node metastasis; clinicopathologic features and patterns of nodal spread. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[18]  John Ludbrook,et al.  Statistical Techniques For Comparing Measurers And Methods Of Measurement: A Critical Review , 2002, Clinical and experimental pharmacology & physiology.

[19]  Y. Doki,et al.  Genetic detection of lymph node micrometastases in patients with gastric carcinoma by multiple‐marker reverse transcriptase‐polymerase chain reaction assay , 2001, Cancer.

[20]  S. Tsujitani,et al.  Significant correlation between micrometastasis in the lymph nodes and reduced expression of E-cadherin in early gastric cancer , 2001, Gastric Cancer.

[21]  M. Okada,et al.  Is segmentectomy with lymph node assessment an alternative to lobectomy for non-small cell lung cancer of 2 cm or smaller? , 2001, The Annals of thoracic surgery.

[22]  A. Jemal,et al.  Recent trends in lung cancer mortality in the United States. , 2001, Journal of the National Cancer Institute.

[23]  J. Deslauriers,et al.  Clinical and surgical staging of non-small cell lung cancer. , 2000, Chest.

[24]  P C Goodman,et al.  Staging non-small cell lung cancer with whole-body PET. , 1999, Radiology.

[25]  P Grenier,et al.  CT demonstration of the 1996 AJCC-UICC regional lymph node classification for lung cancer staging. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.

[26]  U. Pastorino,et al.  Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer. , 1999, The Journal of thoracic and cardiovascular surgery.

[27]  E. van Marck,et al.  Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. , 1997, The European respiratory journal.

[28]  R. Wahl,et al.  Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. , 1994, Radiology.